Search

Your search keyword '"Mark Grose"' showing total 5 results
Start Over Author "Mark Grose" Journal annals of oncology
5 results on '"Mark Grose"'

1. Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Author

Hardev Pandha, Rachel E. Sanborn, M.R. Zibelman, R. Jennens, Charles M. Rudin, Timothy D. Clay, Gavin M. Wright, Christy Ralph, Steven J. O'Day, Emmett V. Schmidt, Sumati Gupta, Mark Grose, Brendan D. Curti, Wallace Akerley, Darren R. Shafren, David Campbell, Jonathan E. Rosenberg, A.G. Hill, David E. Gerber, and D. Day

Subjects
0301 basic medicine, Bladder cancer, business.industry, Coxsackievirus A21, Hematology, Pembrolizumab, medicine.disease, Oncolytic virus, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, medicine, business
Published
2018
Full Text
View/download PDF

2. Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21

Author

Gough G. Au, Hugh Mostafid, Sarbjinder S Sandhu, Darren R. Shafren, Mark Grose, Roberta Karpathy, Hardev Pandha, Mehreen Arif, Nicola E. Annels, David Mansfield, K.J. Harrington, and Alan Melcher

Subjects
0301 basic medicine, business.industry, medicine.medical_treatment, Coxsackievirus A21, Cancer, Hematology, Immunotherapy, medicine.disease, Oncolytic virus, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Phase i ii, Oncology, 030220 oncology & carcinogenesis, Immunology, medicine, Cancer research, Non muscle invasive, business
Published
2016
Full Text
View/download PDF

3. Intravenous coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients: phase Ib KEYNOTE 200 study

Author

Alan Melcher, David Ross Kaufman, Emmett V. Schmidt, Roberta Karpathy, Christy Ralph, Hardev Pandha, Darren R. Shafren, Mark Grose, and K.J. Harrington

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Coxsackievirus A21, Hematology, Pembrolizumab, Advanced cancer, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Immunology, Medicine, business
Published
2016
Full Text
View/download PDF

4. Phase Ib study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma

Author

A. Zloza, K. Spencer, Mark Grose, Janice M. Mehnert, J. Wang, A. Silk, D. Moore, Darren R. Shafren, M. Kane, and Howard L. Kaufman

Subjects
business.industry, Coxsackievirus A21, Hematology, Pembrolizumab, 030204 cardiovascular system & hematology, Virology, Oncolytic virus, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, Medicine, business, Advanced melanoma
Published
2016
Full Text
View/download PDF

5. The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma

Author

Jon M. Richards, Brendan D. Curti, Mark Grose, Robert H.I. Andtbacka, Darren R. Shafren, Roberta Karpathy, and Mark B. Faries

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Coxsackievirus A21, Ipilimumab, Hematology, Immunotherapy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, business, medicine.drug, Advanced melanoma
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results